

[Date]

[Patient\_First\_Name] [Patient\_Last\_Name]

[Patient\_Primary\_Address\_2]

[Patient\_Primary\_Address\_1]

[Patient\_Primary\_City], «Patient\_State» «Patient\_ZIP»

Dear [Patient\_First\_Name] [Patient\_Last\_Name]:

When enrolling in the LEMTRADA REMS, you and your doctor agreed that you will participate in monthly laboratory monitoring until 4 years after your last infusion to monitor for possible side effects.

The lab tests, which are required every 30 days, are important to identify side effects like autoimmune conditions. Please make sure to continue to schedule and go to your monthly lab appointments.

It is also important that you look for symptoms of these side effects by doing your own symptom self-checks, as described in LEMTRADA Treatment and Infusion Reactions Patient Guide that your doctor gave you before you started your LEMTRADA treatment.

As part of the program, you are receiving these monthly reminders by mail for your lab tests. If you have questions about LEMTRADA or your monthly lab monitoring, please call the LEMTRADA REMS at 1-855-676-6326, Monday through Friday, 8:30 am to 8:00 pm ET. In addition, please contact the LEMTRADA REMS if your contact information has changed.

Sincerely,

LEMTRADA REMS



sanofi

©2024 Genzyme Corporation. All rights reserved.

Lemtrada and Sanofi are registered in U.S. Patent and Trademark Office.  
US.MS.LEM.14.10.008-v6-01/2024

  
**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup>  
iv